**Indication** | Follicular lymphoma  
|---|---
**INN** | Vincristine  
**Medicine type** | Chemical agent  
**List type** | Complementary  
**Formulations** | Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate) ; 5 mg in vial (vincristine sulfate) ; 1 mg per mL in vial (vincristine sulfate) ; 2 mg per 2 mL in vial (vincristine sulfate)  
**EML status history** | First added in 2015 (TRS 994)  
Changed in 2021 (TRS 1035)  
**Sex** | All  
**Age** | Adolescents and adults  
**Therapeutic alternatives** | The recommendation is for this specific medicine  
**Patent information** | Patents have expired in most jurisdictions  
Read more about patents.  
**Tags** | Cancer  
**Wikipedia** | Vincristine  
**DrugBank** | Vincristine  

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1mg/mL and 2 mg/2mL) to the EML and EMLc.